Skip to main content
TipRanks
Go Ultimate75% OFF

Shalby Ltd. (SHALBY) AI Stock Analysis

0 Followers
IN:SHALBY

Shalby Ltd.

(NSE:SHALBY)

Select Model
Rating:46Neutral
Price Target:INR 119.00â–¼(-0.29% Downside)
Action:reiterated
Date:08/29/26

The score is primarily pressured by weakening financial quality—negative operating/free cash flow and higher leverage alongside margin compression—despite strong revenue growth. Technicals are also weak with the stock trading below major moving averages and negative MACD. Valuation remains demanding at ~43.7x earnings, offering limited margin of safety.

Positive Factors
Strong Revenue ExpansionThe substantial multi-year increase in revenue demonstrates expanding operating scale and sustained demand for Shalby’s healthcare services. A larger revenue base can support broader clinical capacity, improve utilization, and provide a platform for future earnings growth if profitability stabilizes.
Negative Factors
Negative Cash GenerationSustained negative operating and free cash flow indicates that reported growth is not currently translating into internally generated funding. Continued cash consumption can increase reliance on debt or other financing, constrain investment flexibility, and heighten execution risk over the next several quarters.

Shalby Ltd. (SHALBY) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%IN:SHALBY-45.05%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 12.84B
Dividend Yield
―
Average Volume (3M)
5,356
Price to Earnings (P/E)
33.1
Beta (1Y)
1.01
Revenue Growth
7.27%
EPS Growth
774.36%
Country
India
Employees
2,217
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Shalby Ltd. Business Overview & Revenue Model

Company Description

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic...

Shalby Ltd. Financial Statement Overview

Summary

Strong revenue growth is offset by weaker quality of earnings: margin compression, rising leverage (debt-to-equity increasing to ~0.59 by FY2026), and materially deteriorating cash generation with negative operating and free cash flow in FY2025–FY2026. These factors increase funding and execution risk despite the expanding top line.

Income Statement

58Neutral

Balance Sheet

62Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.04B11.41B10.87B9.34B8.05B6.99B
Gross Profit2.70B2.09B2.02B2.50B3.70B3.05B
EBITDA1.48B1.43B1.60B1.90B1.61B1.30B
Net Income392.06M373.89M62.22M840.77M677.01M541.25M
Balance Sheet
Total Assets18.57B18.39B17.04B16.08B12.81B11.94B
Cash, Cash Equivalents and Short-Term Investments725.92M841.97M1.29B1.08B2.16B2.02B
Total Debt5.85B5.95B4.76B3.78B1.81B1.74B
Total Liabilities8.35B8.33B7.08B6.00B3.54B3.17B
Stockholders Equity10.22B10.05B9.92B10.00B9.28B8.76B
Cash Flow
Free Cash Flow0-1.82B-1.03B-275.11M492.90M-564.77M
Operating Cash Flow0-333.59M-313.01M195.96M677.73M189.17M
Investing Cash Flow0-990.00M-433.53M380.73M-610.59M-602.82M
Financing Cash Flow01.19B822.58M-1.51B-500.24M904.59M

Shalby Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price119.35

Price Trends

50DMA131.71Negative
100DMA147.07Negative
200DMA153.46Negative

Market Momentum

MACD-2.68Negative
RSI40.35Neutral
STOCH18.25Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHALBY, the sentiment is Negative. The current price of 119.35 is below the 20-day moving average (MA) of 120.85, below the 50-day MA of 131.71, and below the 200-day MA of 153.46, indicating a bearish trend. The MACD of -2.68 indicates Negative momentum. The RSI at 40.35 is Neutral, neither overbought nor oversold. The STOCH value of 18.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SHALBY.

Shalby Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SHALBY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:MEDANTAIN:MEDANTA69NeutralINR 387.91B62.41―0.07%26.18%10.09%
IN:MAXHEALTHIN:MAXHEALTH63NeutralINR 994.74B72.13―0.20%15.17%1.63%
IN:APOLLOHOSPIN:APOLLOHOSP62NeutralINR 1.27T56.56―0.23%19.24%34.11%
IN:FORTISIN:FORTIS59NeutralINR 601.70B57.67―0.13%17.50%2.40%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ASTERDMIN:ASTERDM55NeutralINR 643.99B101.11―0.55%50.47%10.73%
IN:SHALBYIN:SHALBY46NeutralINR 13.07B33.14――7.27%774.36%

* General Sector Average

Performance Comparison

-40%-20%0%20%IN:SHALBYIN:APOLLOHOSPIN:ASTERDMIN:FORTISIN:MAXHEALTHIN:MEDANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SHALBY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SHALBYShalby Ltd.119.35-102.70-46.25%
IN:APOLLOHOSPApollo Hospitals Enterprise Limited8811.001408.2719.02%
IN:ASTERDMAster DM Healthcare Ltd.730.1065.209.81%
IN:FORTISFortis Healthcare Ltd.797.00-137.56-14.72%
IN:MAXHEALTHMax Healthcare Institute Ltd1022.00-143.93-12.34%
IN:MEDANTAGlobal Health Limited1434.80222.4318.35%

Shalby Ltd. Corporate Events

Shalby Shares Audio Recording of Q2 FY27 Earnings Call

Nov 4, 2026

Shalby Limited shared the audio recording of its Q2 FY27 earnings conference call held on November 4, 2026. The disclosure enables investors and other stakeholders to access management’s earnings discussion while supporting the company’s regulatory c...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026